Id: acc1201
Group: 2sens
Protein: CDK2
Gene Symbol: CDK2
Protein Id: P24941
Protein Name: CDK2_HUMAN
PTM: phosphorylation
Site: Thr160
Site Sequence: AFGVPVRTYTHEVVTLWYRAP
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: LoVo
Disease Info:
Drug: adapalene
Drug Info: "Adapalene is a topical retinoid medication primarily used for the treatment of mild to moderate acne vulgaris, including comedones, papules, and pustules, by modulating keratinocyte differentiation and reducing inflammation. "
Effect: modulate
Effect Info: Adapalene (ADA) can significantly increase the phosphorylation of CDK2 (at Thr-160) and Rb (at Ser-795) and inhibit tumors.
Note:
Score: 4.0
Pubmed(PMID): 26398439
Sentence Index:
Sentence:

Sequence & Structure:

MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CDK2 DINACICLIB Cyclin-dependent kinase 2 inhibitor 3 Completed chronic lymphocytic leukemia ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed chronic lymphocytic leukemia ClinicalTrials
ClinicalTrials
CDK2 MILCICLIB Cyclin-dependent kinase 2 inhibitor 2 Completed hepatocellular carcinoma ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Terminated chronic lymphocytic leukemia ClinicalTrials
CDK2 AT-7519 Cyclin-dependent kinase inhibitor 2 Completed chronic lymphocytic leukemia ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
ClinicalTrials
CDK2 DINACICLIB Cyclin-dependent kinase 2 inhibitor 2 Terminated acute lymphoblastic leukemia ClinicalTrials
CDK2 DINACICLIB Cyclin-dependent kinase 2 inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed cutaneous melanoma ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed lymphoma ClinicalTrials
ClinicalTrials
CDK2 UCN-01 Cyclin-dependent kinase 2 inhibitor 2 Terminated lymphoma ClinicalTrials
CDK2 RONICICLIB Cyclin-dependent kinase inhibitor 2 Withdrawn neoplasm ClinicalTrials
CDK2 RONICICLIB Cyclin-dependent kinase inhibitor 2 Terminated small cell lung carcinoma ClinicalTrials
CDK2 UCN-01 Cyclin-dependent kinase 2 inhibitor 2 Completed small cell lung carcinoma ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed sarcoma ClinicalTrials
CDK2 UCN-01 Cyclin-dependent kinase 2 inhibitor 2 Terminated melanoma ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed multiple myeloma ClinicalTrials
CDK2 DINACICLIB Cyclin-dependent kinase 2 inhibitor 2 Completed multiple myeloma ClinicalTrials
CDK2 UCN-01 Cyclin-dependent kinase 2 inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
CDK2 SELICICLIB Cyclin-dependent kinase 2 inhibitor 2 Terminated non-small cell lung carcinoma ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
CDK2 ALVOCIDIB Cyclin-dependent kinase 2 inhibitor 2 Completed pancreatic adenocarcinoma ClinicalTrials
CDK2 MILCICLIB Cyclin-dependent kinase 2 inhibitor 2 Terminated Thymoma ClinicalTrials
CDK2 MILCICLIB Cyclin-dependent kinase 2 inhibitor 2 Terminated Thymic Carcinoma ClinicalTrials
CDK2 SELICICLIB Cyclin-dependent kinase 2 inhibitor 2 Recruiting pituitary-dependent Cushing's disease ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CDK2-Thr160
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - P Hepatocellular carcinoma Ubiquitination 29497124
- - U T-cell acute lymphoblastic leukemia Acetylation 34407842
Y 15 U Neuroblastoma Phosphorylation 24349301

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: